Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo

Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for success in finding novel improved therapeutic options for such dismal di...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2020-12, Vol.494, p.73-83
Hauptverfasser:	Le Reste, Pierre Jean, Pineau, Raphael, Voutetakis, Konstantinos, Samal, Juhi, Jégou, Gwénaële, Lhomond, Stéphanie, Gorman, Adrienne M., Samali, Afshin, Patterson, John B., Zeng, Qingping, Pandit, Abhay, Aubry, Marc, Soriano, Nicolas, Etcheverry, Amandine, Chatziioannou, Aristotelis, Mosser, Jean, Avril, Tony, Chevet, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antibodies Benzopyrans - administration & dosage Benzopyrans - pharmacology Brain cancer Brain Neoplasms - genetics Brain Neoplasms - immunology Brain Neoplasms - therapy Cancer Cancer therapies Cell adhesion & migration Cell Line, Tumor Chemotherapy Combined Modality Therapy - methods Craniotomy Drug Therapy Endoplasmic reticulum Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Genomes Glioblastoma Glioblastoma - genetics Glioblastoma - immunology Glioblastoma - therapy Humans Immunocompetence Injections, Intralesional IRE1 Life Sciences Mice Morpholines - administration & dosage Morpholines - pharmacology Neoadjuvant Therapy Patients Principal components analysis Proteins Radiation Radiotherapy Surgery Treatment Outcome Tumor Microenvironment - drug effects Tumors Unfolded Protein Response Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!